ES2082461T3 - Compuesto anticanceroso. - Google Patents

Compuesto anticanceroso.

Info

Publication number
ES2082461T3
ES2082461T3 ES92907670T ES92907670T ES2082461T3 ES 2082461 T3 ES2082461 T3 ES 2082461T3 ES 92907670 T ES92907670 T ES 92907670T ES 92907670 T ES92907670 T ES 92907670T ES 2082461 T3 ES2082461 T3 ES 2082461T3
Authority
ES
Spain
Prior art keywords
pct
nitrogen atom
hydroxy
group
separately selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92907670T
Other languages
English (en)
Inventor
Laurence Hylton Patterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Technology Group Ltd filed Critical British Technology Group Ltd
Application granted granted Critical
Publication of ES2082461T3 publication Critical patent/ES2082461T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/04—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds containing amino-oxide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DE FORMULA (I), DONDE R1 ES FORM 1 O 2 Y R2 ES SEPARADAMENTE SELECCIONADO DE HIDROGENO, FORMS 3 Y 4, DONDE A ES UN GRUPO ALQUILENO C2-4 CON UNA CADENA DE LONGITUD ENTRE N O NH Y N(O)R''R" DE AL MENOS DOS ATOMOS DE CARBONO, R ES UN GRUPO IMIDAZOLIL O TIAZOLIL EN LOS CUALES EL ATOMO DE HIDROGENO TERCIARIO TIENE LA FORMA N-OXIDO, Y R'' Y R" SON SELECCIONADAS SEPARADAMENTE DE GRUPOS ALQUILO C1-4, HIDROALQUILOS C2-4 Y DIHIDROALQUILOS C3-4 EN LOS CUALES EL ATOMO DE CARBONO UNIDO AL ATOMO DE NITROGENO NO PORTA UN GRUPO HIDROXILO Y NINGUN ATOMO DE CARBONO SE SUSTITUYE POR DOS GRUPOS HIDROXILOS, O R'' Y R" JUNTOS SON GRUPO ALQUILENO C2-6 CON EL ATOMO DE HIDROGENO AL QUE ESTAN UNIDOS FORMAN UN GRUPO HETEROCICLICO DE 3 A 7 ATOMOS EN EL ANILLO, Y R3,R4,R% Y R6 SON SELECCIONADOS SEPARADAMENTE DE HIDROGENO, HIDROXILO, HALOGENO, AMINO,ALCOXI C1-4 Y ALCANOILOXI C2-8, Y SALES FISIOLOGICAMENTE ACEPTABLES DE LOS MISMOS SON DE VALOR EN EL TRATAMIENTO DE CANCER.
ES92907670T 1991-04-12 1992-04-10 Compuesto anticanceroso. Expired - Lifetime ES2082461T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919107843A GB9107843D0 (en) 1991-04-12 1991-04-12 Anti-cancer compounds

Publications (1)

Publication Number Publication Date
ES2082461T3 true ES2082461T3 (es) 1996-03-16

Family

ID=10693185

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92907670T Expired - Lifetime ES2082461T3 (es) 1991-04-12 1992-04-10 Compuesto anticanceroso.

Country Status (11)

Country Link
US (1) US5461078A (es)
EP (1) EP0579646B1 (es)
JP (1) JPH06506923A (es)
AT (1) ATE132136T1 (es)
AU (1) AU660883B2 (es)
CA (1) CA2108256A1 (es)
DE (1) DE69207182T2 (es)
ES (1) ES2082461T3 (es)
GB (2) GB9107843D0 (es)
WO (1) WO1992018469A1 (es)
ZA (1) ZA922641B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107852D0 (en) * 1991-04-12 1991-05-29 Patterson Laurence H Anti-cancer compounds
PT1019385E (pt) * 1995-09-15 2004-06-30 Upjohn Co N-oxidos de aminoaril-oxazolidinona
JP2002507557A (ja) * 1998-03-26 2002-03-12 デパートメント オブ ジ アーミー， ユー．エス． ガバメント 抗生物質抵抗性感染の処置のための置換芳香族化合物
RU2349311C1 (ru) * 2007-08-02 2009-03-20 Михаил Владимирович Кутушов Применение дериватов нафталина в качестве средств для лечения онкологических заболеваний
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
CN107056623A (zh) * 2017-05-02 2017-08-18 南京安琪儿生物科技有限公司 一种蓝色溶酶体标记荧光染料的合成新方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1118414A (fr) * 1953-06-19 1956-06-06 Yoshitomi Pharmaceutical Procédé de préparation des nu-oxydes d'amines tertiaires aliphatiques halogénées
GB781237A (en) * 1954-12-14 1957-08-14 Sterling Drug Inc Anthracene derivatives and their preparation
FR1316453A (fr) * 1958-07-05 1963-02-01 Parke Davis & Co Procédé de fabrication de composés acridinylamino-o-crésol, 10-oxyde
US3174994A (en) * 1962-01-30 1965-03-23 Smith Kline French Lab Hypocholesterolemic n-oxide compositions
FR1505351A (fr) * 1966-01-06 1967-12-15 Rhone Poulenc Sa Nouveaux dérivés de l'anthracène et leur préparation
CH517096A (de) * 1968-08-31 1971-12-31 Starogardzkie Zakl Farma Verfahren zur Herstellung neuer, biologisch aktiver 1-Nitro-9-(dialkyl-aminoalkylamino)-akridin-N10-oxide
IL69211A (en) * 1982-07-23 1987-01-30 Warner Lambert Co Substituted anthra(1,9-cd)pyrazol-6(2h)-ones,their preparation and pharmaceutical compositions containing them
US4555572A (en) * 1983-07-19 1985-11-26 Warner-Lambert Company Pyrazolo[3,4,5-kl]acridine compositions and methods for their production and use
US4626540A (en) * 1983-11-08 1986-12-02 Warner-Lambert Company Substituted 1-amino-4-nitro-acridinones and methods of treating bacterial infections and leukemia with them
DE3405330A1 (de) * 1984-02-15 1985-08-22 Sandoz-Patent-GmbH, 7850 Lörrach Neue allylamine, verfahren zu ihrer herstellung und ihre verwendung
US4686218A (en) * 1985-01-30 1987-08-11 Smithkline Beckman Corporation Use of 6-chloro-3-methyl-1H-2,3,4,5-tetrahydro-3-benzazepine-n-oxide, as a prodrug
IN164921B (es) * 1986-07-22 1989-07-08 Hoechst India
GB8923075D0 (en) * 1989-10-13 1989-11-29 Patterson Laurence H Anti-cancer compounds
US4963554A (en) * 1990-02-14 1990-10-16 Ortho Pharmaceutical Corporation 6,7-dimethoxy-1,2-dihydro-2-arylquinazoline-3-oxides

Also Published As

Publication number Publication date
GB2254613A (en) 1992-10-14
ATE132136T1 (de) 1996-01-15
WO1992018469A1 (en) 1992-10-29
GB9107843D0 (en) 1991-05-29
GB9207957D0 (en) 1992-05-27
AU660883B2 (en) 1995-07-06
DE69207182T2 (de) 1996-05-15
GB2254613B (en) 1995-01-25
CA2108256A1 (en) 1992-10-13
US5461078A (en) 1995-10-24
ZA922641B (en) 1993-10-11
EP0579646B1 (en) 1995-12-27
AU1537692A (en) 1992-11-17
DE69207182D1 (en) 1996-02-08
JPH06506923A (ja) 1994-08-04
EP0579646A1 (en) 1994-01-26

Similar Documents

Publication Publication Date Title
ATE101181T1 (de) Anti-krebs-verbindungen.
MY108261A (en) Water soluble camptothecin derivatives
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
IL103944A (en) Piperazine derivatives, their preparation and pharmaceutical compositions containing them
KR950700278A (ko) 벤조사이클로헵텐, 벤조옥세핀 및 벤조티에핀(benzocycloheptenes, benzoxepines and benzothiepines)
ES2082461T3 (es) Compuesto anticanceroso.
TW333532B (en) Benzopyrans
DK0591058T3 (da) Ellipticinderivater med antitumoraktivitet
ATE83776T1 (de) 1,2-benzisoxazole und 1,2-benzisothiazole.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 579646

Country of ref document: ES